title: Norfloxacin for the prophylaxis of travelers' diarrhea in U.S. military personnel.
abstract: Norfloxacin, an oral fluoroquinolone (dose 400 mg daily), was compared to a placebo in a double blinded randomized trial for the prophylaxis of travelers' diarrhea. The study was of U.S. Navy and Marine Corps personnel on shore leave in Alexandria, Egypt. A total of 222 subjects were available (105 norfloxacin, 117 placebo). In the placebo group, 26% (30/117) developed acute diarrhea vs. 2% (2/105) in the norfloxacin group. There were no significant side effects in either group.
authors.affiliation: U.S. Naval Medical Research Unit No. 3, Cairo, Egypt.
authors.forename: D A
authors.initials: DA
authors.lastname: Scott
authors.forename: R L
authors.initials: RL
authors.lastname: Haberberger
authors.forename: S A
authors.initials: SA
authors.lastname: Thornton
authors.forename: K C
authors.initials: KC
authors.lastname: Hyams
mesh_terms: D000208:Acute Disease; D000328:Adult; D003906:Developing Countries; D003967:Diarrhea / Q000517:prevention & control*; D004534:Egypt; D005500:Follow-Up Studies; D006801:Humans; D008889:Military Personnel; D009643:Norfloxacin / Q000009:adverse effects / Q000627:therapeutic use*; D010349:Patient Compliance; D016032:Randomized Controlled Trials as Topic; D012767:Ships; D011795:Surveys and Questionnaires; D014195:Travel; D014481:United States
chemical_list: D009643:Norfloxacin